ISRCTN70706542 https://doi.org/10.1186/ISRCTN70706542

The effect of Der p 1 inhalation on bronchial responsiveness to inhaled cat allergen in asthmatics sensitised to cat but not to house dust mite

Submission date
12/09/2003

Recruitment status
No longer recruiting

Registration date
12/09/2003

Overall study status
Completed

Last Edited
11/10/2016

Condition category
Respiratory

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[_] Results
[_] Individual participant data
[_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Ashley Woodcock

Contact details
North West Lung Centre
South Manchester University Hospitals NHS Trust
Wythenshawe Hospital
Southmoor Road
Manchester
United Kingdom
M23 9LT
+44 (0)161 291 5873
ashley.woodcock@manchester.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0226111705

Study information

Scientific Title
The effect of Der p 1 inhalation on bronchial responsiveness to inhaled cat allergen in asthmatics sensitised to cat but not to house dust mite

Study objectives
To detect whether bronchial responsiveness to cat allergen, in a subject sensitised to cat, but not dust mite, may be enhanced by the presence of Dermatophagoides pteronyssinus 1 (Der p 1), a cysteine peptidase allergen.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Double-blind placebo-controlled randomised cross-over study

Primary study design
Interventional

Secondary study design
Randomised cross over trial

Study setting(s)
Not specified

Study type(s)
Other

Participant information sheet
Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied
Asthma

Interventions
Double-blind, placebo-controlled, randomised, cross-over study. Patients are randomised to:
1. Dermatophagoides pteronyssinus 1 (Der p 1), a cysteine peptidase allergen
2. Placebo

Intervention Type

Other

Primary outcome measure
The measure of cat allergen PD20, that is the cumulative dose of cat allergen required to cause a 20% fall in forced expiratory volume in one second (FEV1).

Secondary outcome measures
Not provided at time of registration

Overall study start date
27/05/2002

Completion date
31/12/2003

Eligibility

Key inclusion criteria
10 subjects, volunteers selected from the MEU database who have had previous skin prick testing and identified as being sensitised to cat and not house dust mite

Participant type(s)
Healthy volunteer

Age group
Adult

Sex
Both

Target number of participants
10

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
27/05/2002

Date of final enrolment
31/12/2003

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
North West Lung Centre
Manchester
United Kingdom
M23 9LT

Sponsor information

Organisation
Department of Health (UK)

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.doh.gov.uk

Funder(s)

Funder type
Charity

Funder Name
North West Lung Centre Charity (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration